Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase

被引：11
|
作者：
Rab, Minke A. E. [1 ,2 ]
van Oirschot, Brigitte A. [2 ]
van Straaten, Stephanie [3 ]
Biemond, Bart J. [4 ]
Bos, Jennifer [2 ]
Kosinski, Penelope A. [5 ]
Kung, Charles [5 ]
van Beers, Eduard J. [1 ]
van Wijk, Richard [6 ]
机构：
[1] Univ Utrecht, UMC Utrecht, Creveldklin, Utrecht, Netherlands
[2] Univ Utrecht, Dept Clin Chem & Haematol, UMC Utrecht, Utrecht, Netherlands
[3] Elisabeth TweeSteden Hosp, Dept Pediat, Tilburg, Netherlands
[4] Acad Med Ctr, Dept Clin Hematol, Amsterdam UMC, Amsterdam, Netherlands
[5] Agios Pharmaceut Inc, Cambridge, MA USA
[6] Univ Med Ctr Utrecht, Lab Clin Chem & Hematol, Utrecht, Netherlands
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-129996
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3506
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
    van Dijk, Myrthe J.
    van der Veen, Sigrid
    Rab, Minke A. E.
    van Oirschot, Brigitte A.
    Bos, Jennifer
    Derichs, Cleo
    Rijneveld, Anita W.
    Cnossen, Marjon H.
    Nur, Erfan
    Biemond, Bart J.
    Bartels, Marije
    Jans, Judith J. M.
    van Wijk, Richard
    van Beers, Eduard J.
    BLOOD, 2022, 140
  • [32] Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused: A Phase 3, Open-Label, Multicenter, Study (ACTIVATE-T) in Progress
    Lynch, Megan
    Hua, Lei
    Mix, Chris
    Porter, John B.
    BLOOD, 2019, 134
  • [33] PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF AG-348, A FIRST-IN-CLASS ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R, IN HEALTHY SUBJECTS
    Yang, H.
    Merica, E.
    Chen, Y.
    Cohen, M.
    Goldwater, R.
    Kim, H.
    Kosinski, P.
    Kung, C.
    Goldwasser, M.
    Silver, B.
    Utley, L.
    Agresta, S.
    HAEMATOLOGICA, 2015, 100 : 18 - 18
  • [34] Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease[S]
    Schroeder, Patricia
    Fulzele, Keertik
    Forsyth, Sanjeev
    Ribadeneira, Maria D.
    Guichard, Sylvie
    Wilker, Erik
    Marshall, C. Gary
    Drake, Adam
    Fessler, Rose
    Konstantinidis, Diamantis G.
    Seu, Katie G.
    Kalfa, Theodosia A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2022, 380 (03): : 210 - 219
  • [35] Voxelotor and Red Blood Cell Pyruvate Kinase Activator Affect Clot Strength in Sickle Cell Disease
    Sekyonda, Zoe
    Abonga, Calvin
    Delianides, Christopher A.
    Oshabaheebwa, Solomon
    Little, Jane A.
    Suster, Michael A.
    Mohseni, Pedram
    Gurkan, Umut A.
    BLOOD, 2023, 142
  • [36] Phenotypic Corrections of Ex Vivo Erythrocytes Derived from Chronic Hemolytic Anemia Patients Due to Kruppel-like Factor 1 (KLF-1) Mutations By AG-348: A Novel Synthetic Pyruvate Kinase Activator
    Suksangpleng, Thidarat
    Tachavanich, Kalaya
    Riolueang, Suchada
    Ekwattanakit, Supachai
    Viprakasit, Vip
    BLOOD, 2019, 134
  • [37] Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress
    van Beers, Eduard J.
    Judge, Malia P.
    Hua, Lei
    Mix, Chris
    BLOOD, 2019, 134
  • [38] Phase 1 Single- and Multiple-Ascending-Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers
    Yang, Hua
    Merica, Elizabeth
    Chen, Yue
    Cohen, Marvin
    Goldwater, Ronald
    Kosinski, Penelope A.
    Kung, Charles
    Yuan, Zheng
    Silverman, Lee
    Goldwasser, Meredith
    Silver, Bruce A.
    Agresta, Sam
    Barbier, Ann J.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 246 - 259
  • [39] Ex Vivo Treatment By Mitapivat, an Allosteric Pyruvate Kinase Activator, Reduced Oxidative Stress and Promoted Terminal Erythropoiesis in a Severe Hemolytic Anemia Patient Due to Kr.ppel-like Factor 1 Mutations
    Suksangpleng, Thidarat
    Tachavanich, Kalaya
    Viprakasit, Vip
    BLOOD, 2023, 142
  • [40] Molecular modelling of human red blood cell pyruvate kinase: Structural implications of a novel G(1091) to A mutation causing severe nonspherocytic hemolytic anemia
    vanSolinge, WW
    Kraaijenhagen, RJ
    Rijksen, G
    vanWijk, R
    Stoffer, BB
    Gajhede, M
    Nielsen, FC
    BLOOD, 1997, 90 (12) : 4987 - 4995
12345